A Review of Therapy for Primary Membranous Nephropathy Post-MENTOR

Vinay Srinivasa


Primary membranous nephropathy (PMN) is the most common cause of nephrotic syndrome in adults worldwide. Recent evidence confirms an autoimmune pathogenesis highlighted by the discovery of the phospholipase A2 receptor (PLA2R) antigen. PLA2R serves as both a marker and a guide for treatment. Traditional treatments, including alkylating agents and calcineurin inhibitors, have been associated with adverse risk profiles. Consequently, alternative therapies have been developed. Rituximab is a promising addition to the therapeutic armamentarium of PMN. However, there are few head-to-head trials comparing rituximab with cyclophosphamide. In this clinical review, the results of the MENTOR, STARMEN, and RI-CYCLO trials are discussed and evaluated. Based on the results of these trials, a more personalized treatment approach is needed.

World J Nephrol Urol. 2021;10(1):7-11
doi: https://doi.org/10.14740/wjnu426


Primary membranous nephropathy; Personalizing therapy; PLA2R; Rituximab; MENTOR

Full Text: HTML PDF

Browse  Journals  


Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

Journal of Neurology Research

International Journal of Clinical Pediatrics






World Journal of Nephrology & Urology, quarterly, ISSN 1927-1239 (print), 1927-1247 (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)

This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.wjnu.org   editorial contact: editor@wjnu.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada
© Elmer Press Inc. All Rights Reserved.

Disclaimer: The views and opinions expressed in the published articles are those of the authors and do not necessarily reflect the views or opinions of the editors and Elmer Press Inc. This website is provided for medical research and informational purposes only and does not constitute any medical advice or professional services. The information provided in this journal should not be used for diagnosis and treatment, those seeking medical advice should always consult with a licensed physician.